These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 38012534)

  • 21. Evaluation of Immunogenicity of Nivolumab Monotherapy and Its Clinical Relevance in Patients With Metastatic Solid Tumors.
    Agrawal S; Statkevich P; Bajaj G; Feng Y; Saeger S; Desai DD; Park JS; Waxman IM; Roy A; Gupta M
    J Clin Pharmacol; 2017 Mar; 57(3):394-400. PubMed ID: 27557786
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term Immunogenicity of Elosulfase Alfa in the Treatment of Morquio A Syndrome: Results From MOR-005, a Phase III Extension Study.
    Long B; Tompkins T; Decker C; Jesaitis L; Khan S; Slasor P; Harmatz P; O'Neill CA; Schweighardt B
    Clin Ther; 2017 Jan; 39(1):118-129.e3. PubMed ID: 27955919
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sotatercept, a soluble activin receptor type 2A IgG-Fc fusion protein for the treatment of anemia and bone loss.
    Raje N; Vallet S
    Curr Opin Mol Ther; 2010 Oct; 12(5):586-97. PubMed ID: 20886391
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low incidence of anti-drug antibodies in patients with type 2 diabetes treated with once-weekly glucagon-like peptide-1 receptor agonist dulaglutide.
    Milicevic Z; Anglin G; Harper K; Konrad RJ; Skrivanek Z; Glaesner W; Karanikas CA; Mace K
    Diabetes Obes Metab; 2016 May; 18(5):533-6. PubMed ID: 26847401
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial.
    Komrokji R; Garcia-Manero G; Ades L; Prebet T; Steensma DP; Jurcic JG; Sekeres MA; Berdeja J; Savona MR; Beyne-Rauzy O; Stamatoullas A; DeZern AE; Delaunay J; Borthakur G; Rifkin R; Boyd TE; Laadem A; Vo B; Zhang J; Puccio-Pick M; Attie KM; Fenaux P; List AF
    Lancet Haematol; 2018 Feb; 5(2):e63-e72. PubMed ID: 29331635
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sotatercept as a next-generation therapy for pulmonary arterial hypertension: insights from the STELLAR trial.
    Kopeć G
    Cardiovasc Res; 2023 Dec; 119(16):e155-e157. PubMed ID: 37584249
    [No Abstract]   [Full Text] [Related]  

  • 27. A Phase 1 first-in-human study of the safety, tolerability, and pharmacokinetics of the ROBO2 fusion protein PF-06730512 in healthy participants.
    Lim CN; Kantaridis C; Huyghe I; Gorman D; Berasi S; Sonnenberg GE
    Pharmacol Res Perspect; 2021 Aug; 9(4):e00813. PubMed ID: 34369667
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis.
    Reich K; Blauvelt A; Armstrong A; Langley RG; Fox T; Huang J; Papavassilis C; Liang E; Lloyd P; Bruin G
    Br J Dermatol; 2017 Mar; 176(3):752-758. PubMed ID: 27518376
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of antidrug antibodies in ustekinumab therapy and the impact of methotrexate.
    Mojtahed Poor S; Henke M; Ulshöfer T; Köhm M; Behrens F; Burkhardt H; Schiffmann S
    Rheumatology (Oxford); 2023 Dec; 62(12):3993-3999. PubMed ID: 37079726
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity of avelumab in patients with metastatic Merkel cell carcinoma or advanced urothelial carcinoma.
    Hu P; Dai HI; Bourdage J; Zhou D; Trang K; Kowalski K; Bello C; Hibma J; Khandelwal A; Cowan K; Dong J; Venkatakrishnan K; Gao W
    Clin Transl Sci; 2024 Mar; 17(3):e13730. PubMed ID: 38411318
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity of pembrolizumab in patients with advanced tumors.
    van Vugt MJH; Stone JA; De Greef RHJMM; Snyder ES; Lipka L; Turner DC; Chain A; Lala M; Li M; Robey SH; Kondic AG; De Alwis D; Mayawala K; Jain L; Freshwater T
    J Immunother Cancer; 2019 Aug; 7(1):212. PubMed ID: 31395089
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial.
    Sitbon O; Bosch J; Cottreel E; Csonka D; de Groote P; Hoeper MM; Kim NH; Martin N; Savale L; Krowka M
    Lancet Respir Med; 2019 Jul; 7(7):594-604. PubMed ID: 31178422
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity of Sarilumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant to Disease-Modifying Antirheumatic Drugs.
    Wells AF; Parrino J; Mangan EK; Paccaly A; Lin Y; Xu C; Fan C; Graham NMH; van Hoogstraten H; Torri A
    Rheumatol Ther; 2019 Sep; 6(3):339-352. PubMed ID: 31090044
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ralinepag Phase II Open-Label Extension Study in Patients with Pulmonary Arterial Hypertension.
    Barberà J; Jansa P; Klings E; Ristić A; Keogh A; Solum D; Rao Y; Grover R; Saib I; Sood N
    Adv Ther; 2024 Mar; 41(3):1062-1074. PubMed ID: 38198043
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antidrug antibody detection for adalimumab depends on the type of assay used: an experimental approach to help clinicians interpret diagnostic data.
    Ruwaard J; Marsman AF; Nurmohamed MT; van der Horst-Bruinsma IE; Te Velthuis H; Bloem K; de Vries A; Rispens T; Wolbink G
    Clin Exp Rheumatol; 2019; 37(5):756-761. PubMed ID: 30943139
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emerging biologics for the treatment of pulmonary arterial hypertension.
    Hye T; Hossain MR; Saha D; Foyez T; Ahsan F
    J Drug Target; 2023 Jun; 31(5):1-15. PubMed ID: 37026714
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of ambrisentan in Chinese patients with connective tissue disease-pulmonary arterial hypertension: a post-hoc analysis.
    Li M; Jing ZC; Li Y; Huo Y; Yu Z; Zhang G; Zhu P; Liu J; Ji Q; Wu B; Zhong J; Wang P; Zhu W; Zeng X
    BMC Cardiovasc Disord; 2020 Jul; 20(1):339. PubMed ID: 32680480
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Safety of Udenafil for the Treatment of Pulmonary Arterial Hypertension: a Placebo-controlled, Double-blind, Phase IIb Clinical Trial.
    Chang HJ; Song S; Chang SA; Kim HK; Jung HO; Choi JH; Lee JS; Kim KH; Jeong JO; Lee JH; Kim DK
    Clin Ther; 2019 Aug; 41(8):1499-1507. PubMed ID: 31202506
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: Fifty-Two-Week Phase III Randomized Study Results.
    Weinblatt ME; Baranauskaite A; Dokoupilova E; Zielinska A; Jaworski J; Racewicz A; Pileckyte M; Jedrychowicz-Rosiak K; Baek I; Ghil J
    Arthritis Rheumatol; 2018 Jun; 70(6):832-840. PubMed ID: 29439289
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pulmonary Artery Denervation for Pulmonary Arterial Hypertension: A Sham-Controlled Randomized PADN-CFDA Trial.
    Zhang H; Wei Y; Zhang C; Yang Z; Kan J; Gu H; Fan F; Gu H; Wang Q; Xie D; Zhang G; Guo X; Yin Y; Jin B; Zhou H; Yang Z; Wang Z; Xin Y; Zhang C; Meng L; Wang X; Sun J; Zhao C; Zhang J; Yan X; Chen F; Yao C; Stone GW; Chen SL
    JACC Cardiovasc Interv; 2022 Dec; 15(23):2412-2423. PubMed ID: 36121246
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.